SS-31 (Elamipretide)

At a glance

Standard Protocol

Alternative Titration 1

Alternative Titration 2

Energy protocols are usually about mitochondrial or metabolic signaling. The logic is timing around meals/training, avoiding late-day stimulation, and watching sleep, glucose, blood pressure, and overtraining signals. Entry context: target (Inner mitochondrial membrane (Cardiolipin binding)); route Subcutaneous; timing Morning. Unapproved or source-dataset dosing tables are hypotheses, not recommendations.

• Mild localized injection site irritation: the most commonly and practically consistently reported adverse effect; redness, mild tenderness, minor swelling at the subcutaneous injection site; rated mild in clinical trial data.
• Injection site bruising: with frequent administration (5x/week protocols); site rotation mitigates accumulation.
• Mild fatigue during the initiation phase: reported in early weeks; consistent with mitochondrial membrane remodeling; resolves as the cardiolipin stabilization effect establishes.
• Headache: mild; uncommon.
• Nausea: rare; mild; self-limiting.
• No significant systemic adverse effects documented in Phase 2/3 clinical trial data: the clinical trial program for elamipretide (SS-31) in Barth syndrome and primary mitochondrial myopathy has demonstrated a favorable tolerability profile with no dose-limiting toxicities or serious adverse events attributed to the compound in published interim data.
• No endocrine disruption: SS-31 has no known receptor activity outside the mitochondrial membrane; does not affect the HPA axis, sex hormone pathways, or thyroid function.
• Potential for pathological energy provision to tumor cells (theoretical): the mechanistic concern for cancer contraindication; not documented as a clinical adverse event.

• Active malignancy: SS-31's enhancement of mitochondrial electron transport chain efficiency and ATP production is not cancer-cell-selective; providing superior bioenergetic infrastructure to rapidly dividing tumor cells is a theoretical oncological concern.
• Known hypersensitivity to SS-31 (elamipretide), D-amino acid peptides, or formulation excipients.
• Pregnancy: mitochondrial membrane potential regulation is critical in early embryonic development; exogenous cardiolipin-binding peptide safety in pregnancy is not established.
• Breastfeeding: no safety data.
• Pediatric use: no data; mitochondrial function in developing tissues may respond differently.
• Severe cardiovascular instability: while SS-31 is being investigated for cardioprotection, acute cardiac decompensation may not be a stable clinical context for research-grade compound administration.
• Subjects with primary mitochondrial diseases seeking therapeutic use: SS-31/elamipretide has active clinical trial programs for these conditions; use in these contexts should be through formal clinical trial enrollment rather than research-grade compound protocols.

Synergistic / related

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://pubmed.ncbi.nlm.nih.gov/?term=SS-31+%28Elamipretide%29